Multimodal Clinical Decision Support for Post-Acute Care

PAC settings need better clinical decisions. Scienza Health's digitalhumanOS™ uses speech biomarkers and visual data to enhance patient care. The Scienza Health digitalhumanOS™ platform offers screening capabilities, analyzing over 2,500 speech biomarkers to provide rapid insights into a patient's cognitive and mental well-being. This technology is 510(k) REGISTERED and HIPAA compliant.

The Power of Multimodal Data in Post-Acute Care

Traditional clinical assessments often rely on a single data point, such as a questionnaire or a brief observation. Multimodal clinical decision support enhances these assessments by integrating multiple sources of information, primarily speech biomarkers and visual data. This approach offers a more complete and nuanced understanding of a patient's condition. By analyzing subtle variations in speech patterns, including tone, pace, and articulation, along with visual cues, the digitalhumanOS platform can detect early indicators of cognitive decline, depression, and other conditions that might otherwise go unnoticed. The integration of these diverse data streams contributes to a more accurate and reliable screening process, leading to better-informed clinical decisions and improved patient outcomes. GIA™ screens; she does not diagnose. A clinician reviews and approves results before they enter the clinical record.

Unlocking Insights with Speech Biomarkers

Speech is a complex and multifaceted form of communication that reflects a wide range of cognitive and emotional processes. Speech biomarkers, derived from the analysis of speech patterns, can provide valuable insights into a patient's mental and cognitive health. The Scienza Health platform analyzes over 2,500 speech biomarkers, including acoustic features, linguistic patterns, and vocal dynamics. These biomarkers can reveal subtle changes in cognitive function, emotional state, and neurological health. For example, changes in speech rate, pitch, or articulation can be indicative of cognitive impairment, depression, or even Parkinson's disease. By using the power of speech biomarkers, clinicians can gain a more objective and data-driven understanding of a patient's condition, leading to earlier detection and more effective interventions. Our Parkinson's screening, for example, has an AUC of 0.97.

Improving Accuracy and Efficiency in Screening

One of the key advantages of multimodal clinical decision support is its ability to improve the accuracy and efficiency of screening processes. Traditional screening methods can be time-consuming and resource-intensive, often requiring extensive manual data collection and analysis. The digitalhumanOS platform automates much of this process, providing rapid and objective results in under 60 seconds. This allows clinicians to screen more patients in less time, freeing up valuable resources for other important tasks. Furthermore, the platform's high accuracy rates – for example, 81.6% for depression screening, 77.5% for anxiety, and 80.0% for PTSD – ensure that potential issues are identified early, leading to more timely and effective interventions. The integration with Samsung Health Grade Galaxy devices with Samsung Knox ensures data security and patient privacy, with GIA speaking 92 languages.

direct Integration with Existing EHR Systems

To maximize its impact, multimodal clinical decision support must directly integrate with existing electronic health record (EHR) systems. The Scienza Health platform is designed to integrate with leading EHR systems, including PointClickCare, Epic, Cerner, MatrixCare. This integration allows for the direct flow of data between the platform and the EHR, ensuring that clinicians have access to the most up-to-date information when making clinical decisions. Furthermore, the integration with EHR systems allows for the automatic documentation of screening results, reducing the burden on clinicians and improving the accuracy of patient records. ADLs and IADLs can be administered by GIA, with results written back to the EHR. CPT codes 96127, 96116, and 99309 are supported.

Addressing Undiagnosed Conditions in Post-Acute Care

Many conditions, such as tardive dyskinesia (TD) and mild cognitive impairment (MCI), often go undiagnosed in post-acute care settings. Studies show that 98.5% of TD cases remain undiagnosed, and 92% of the 12 million Americans with MCI are unaware of their condition. This lack of awareness can have significant consequences, leading to delayed treatment and poorer outcomes. Multimodal clinical decision support can play a critical role in addressing this issue by providing a more sensitive and objective screening tool for these conditions. By detecting early indicators of TD, MCI, and other conditions, the digitalhumanOS platform can help clinicians identify patients who may benefit from further evaluation and treatment. CMS F-Tag 758 addresses unnecessary drugs; our platform can assist in reducing reliance on them.

The digitalhumanOS Platform: A complete approach

The Scienza Health digitalhumanOS platform offers a complete approach for multimodal clinical decision support in post-acute care. The platform's ability to analyze over 2,500 speech biomarkers, combined with its direct integration with existing EHR systems and its high accuracy rates, makes it a valuable tool for improving patient care and outcomes. With the ability to screen for 46 conditions (21 live, 25 coming soon) in under 5 minutes and deliver results in 60 seconds, the digitalhumanOS platform empowers clinicians to make better-informed decisions, leading to more timely and effective interventions. The platform has been used with 12.3M patients and 27B clinical events, demonstrating its scalability and reliability in real-world settings.

Conclusion

Multimodal clinical decision support is transforming post-acute care by providing clinicians with the tools they need to make better-informed decisions and improve patient outcomes. The Scienza Health digitalhumanOS platform, with its ability to analyze over 2,500 speech biomarkers and integrate with existing EHR systems, offers a complete approach for screening a wide range of conditions. By using the power of multimodal data, clinicians can detect early indicators of cognitive decline, depression, and other conditions, leading to more timely and effective interventions. If you're interested in exploring how the digitalhumanOS platform can benefit your organization, request a demo or clinical deployment today.